The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I, open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in MET.
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena; Presagia
Consulting or Advisory Role - Alphasights; Axiom Biotechnologies; Bayer; Genentech; Gerson Lehrman Group; GroupH; Guidepoint Global; Infinity Pharmaceuticals; Medscape; Merrimack; Numab; Pfizer; PrimE Oncology; Seagen; Takeda; Trieza Therapeutics; WebMD
Research Funding - Abbvie; Adaptimmune; Aldai Norte; Amgen; AstraZeneca/MedImmune; Bayer; Daiichi Sankyo; Fate Therapeutics; Genentech; Infinity Pharmaceuticals; Kite, a Gilead company; Kura Oncology; MedImmune; Mirati Therapeutics; Molecular Templates; National Cancer Institute; Pfizer; Seagen; Shattuck Labs; TCR2 Therapeutics; TP Therapeutics
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer
 
Shiraj Sen
Consulting or Advisory Role - Daiichi Sankyo (Inst)
Research Funding - BioAtla (Inst); Exelixis (Inst); Jacobio (Inst); Loxo (Inst)
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer
 
Rebecca Suk Heist
Honoraria - Chugai/Roche
Consulting or Advisory Role - Apollomics; Boehringer Ingelheim; Novartis; Tarveda Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Exelixis (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
 
Shirish M. Gadgeel
Honoraria - AstraZeneca; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Novocure; Takeda; Xcovery
Research Funding - Aeglea Biotherapeutics (Inst); ARIAD/Takeda (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Lycera (Inst); Merck; Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck
Other Relationship - AstraZeneca
 
Zachary Franklin Zimmerman
Employment - Turning Point Therapeutics
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Boehringer Ingelheim; G1 Therapeutics; Genentech/Roche; Loxo; Novartis; Takeda
Research Funding - BeyondSpring Pharmaceuticals